Study suggests an unfavorable association of early-life behavioral problems with adulthood sleep health, underlining the importance of treating behavioral problems in children and addressing insomnia from a life-course perspective.
The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.
The Food and Drug Administration (FDA) approved Wakix (pitolisant; Harmony Biosciences) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.
The treatment of veterans with chronic pain and insomnia with cognitive behavioral therapy for insomnia may improve sleep and mood, but not pain.
Pear Therapeutics is seeking marketing authorization from the Food and Drug Administration (FDA) for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.
De facto medical use of cannabis for symptom relief is common among adult-use dispensary customers in Colorado.
Stimulus control therapy and sleep restriction therapy are viable single-component treatments for chronic insomnia.
A new Boxed Warning will be required in the prescribing information for several insomnia medications following reports of serious injuries and deaths associated with complex sleep behaviors where patients engaged in activities while not fully awake.
Cognitive behavioral therapy is an effective nonpharmacologic treatment for insomnia during pregnancy.
Predictors of neurodegeneration from idiopathic REM sleep behavior disorder (iRBD) have been identified.